Frontiers in Immunology (Jan 2021)

Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid

  • S. Morteza Seyed Jafari,
  • Laurence Feldmeyer,
  • Simon Bossart,
  • Dagmar Simon,
  • Christoph Schlapbach,
  • Luca Borradori

DOI
https://doi.org/10.3389/fimmu.2020.611549
Journal volume & issue
Vol. 11

Abstract

Read online

Bullous pemphigoid (BP) is a blistering autoimmune skin disease. Omalizumab, a monoclonal antibody directed to IgE, showed a beneficial effect in treatment of recalcitrant BP in case series. More recently, dupilumab, an interleukin (IL)-4-receptor alpha antagonist, also showed promising preliminary results. We describe a patient with refractory BP who showed a complete response to a combination therapy with omalizumab and dupilumab.

Keywords